The House Committee on Energy and Commerce has cleared proposed legislation that could bring back the FDA’s rare pediatric ...

DB1, a capsid developed by Shape Therapeutics, to deliver therapies to the brain, including VectorY’s developmental ...

After a tension-packed two days that saw recommended changes to the MMRV vaccine schedule and COVID-19 vaccine access, as ...

Bluebird bio has re-emerged after a private equity buyout as Genetix Biotherapeutics, marking a return to its roots and a new ...

The star of the acquisition, which includes a contingent value right of $6 per share, is pegozafermin, an FGF21 analog in ...

BMO Capital Markets analysts said the first day of the CDC vaccine advisory committee meeting Thursday had anti-vaccine ...

This year, Novo Nordisk and Merck announced significant layoffs, with Novo planning to axe about 9,000 employees and Merck ...

Nektar Therapeutics still needs to establish what differentiates rezpeg from other atopic dermatitis therapies, according to ...

Both BMS and Novo Nordisk have, in recent months, announced steep layoffs as they strive to cut back on costs.

While the FDA is trumpeting this new initiative as “sweeping reforms” to the way drug companies can advertise, experts say ...

Brepocitinib remains “ahead of competition” in the dermatomyositis space, according to analysts at Leerink, who projected ...

Supporting Lexicon Pharmaceuticals’ decision to advance the non-opioid analgesic pilavapadin into late-stage ...